Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in anti-TNF inadequate responder rheumatoid arthritis
2011-006058-94Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in rheumatoid arthritis (RA) (3 arms), sponsored by Novartis. Primary endpoint: ACR20. Started Jul 2012; status: terminated.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-006058-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006058-94.